

NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of \$10 per share. The gross proceeds of the offering to the Company are expected to be approximately \$45 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price.

The closing of the offering is expected to occur on or about July 19, 2021, subject to the satisfaction of customary closing conditions.

Piper Sandler is acting as sole book-runner for the offering. Ladenburg Thalmann & Co. Inc., Roth Capital Partners and Aegis Capital Corp. are acting as co-managers for the offering.

The Company intends to use the net proceeds of the offering to fund the ongoing clinical development of its three lead product candidates, IMU-838, IMU-935 and IMU-856, and for other general corporate purposes.

The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-250083) previously filed with the Securities and Exchange Commission ("SEC") on November 13, 2020, which registration statement was declared effective on November 24, 2020.

A preliminary prospectus supplement relating to the offering was filed with the SEC on July 14, 2021 and is available on the SEC's website at [www.sec.gov](http://www.sec.gov). The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website. Before investing in the offering, you should read each of the prospectus supplement and accompanying prospectus relating to the offering in their entirety as well as the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and accompanying prospectus relating to the offering, which provide more information about the Company and the offering. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, from Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by email at [prospectus@psc.com](mailto:prospectus@psc.com), or by telephone at (800) 747-3924.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Immunic, Inc.**

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR $\gamma$ t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: [www.imux.com](http://www.imux.com).

### **Forward Looking Statements**

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release regarding the proposed offering, the expected size of the proposed offering, the expected size of the underwriters' option with respect to the proposed offering, the satisfaction of the customary closing conditions of the offering, the completion of the contemplated offering, strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management, including in relation to Immunic's development programs, are forward-looking statements. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking

statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including those set forth in the sections captioned "Risk Factors" in Immunic's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, subsequent Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Copies of these filings are available online at [www.sec.gov](http://www.sec.gov) or [ir.imux.com/sec-filings](http://ir.imux.com/sec-filings). Any forward-looking statement made in this press release speaks only as of the date of this press release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

### **Contact Information**

Immunic, Inc.  
Jessica Breu  
Head of Investor Relations and Communications  
+49 89 2080 477 09  
[jessica.breu@imux.com](mailto:jessica.breu@imux.com)

Or

Rx Communications Group  
Paula Schwartz  
+1-917-322-2216  
[immunic@rxir.com](mailto:immunic@rxir.com)

SOURCE Immunic, Inc.

---

<https://ir.imux.com/2021-07-15-Immunic,-Inc-Announces-Pricing-of-45-Million-Public-Offering-of-Common-Stock>